Lucid Diligence Brief: GSK licenses Empirico's siRNA in COPD
Lucid Diligence Brief: GSK licenses Empirico's siRNA in COPD Professional…
ATS 2025 Preview: Key Respiratory Highlights To Watch
ATS 2025 at a glance Prepare for ATS 2025 with LucidQuest’s concise preview,…
Respiratory Weekly News - May 16th 2025
Lung & Respiratory Health Breakthroughs: IPF Patient Voices, Asthma Trial…
How our strategic intelligence helped a respiratory brand, understand the future landscape and adapt its clinical development program (CDP).
The Challenge: Staying updated with the ever-changing competitive landscape in…
How we helped a specialty respiratory company understand the "trends" of severe asthma and COPD assets and position itself strategically.
The Challenge: Staying updated with emerging trends in the respiratory market…
How a leading global player in the respiratory space worked towards speedier access to Russia and China
The Challenge: Leading multinational Pharma company wants to dive deep into key…